Zymeworks Announced Saturday At ESMO, Phase 1 ZW191 Data Showing 64.5% Confirmed Objective Response Rate At 6.4 Mg/Kg Dose In Patients With High-Grade Serous Platinum-Resistant Ovarian Cancer
Share
Why It Matters
Zymeworks tested a new cancer medicine on sick patients. Early results showed the drug helped about 6 out of 10 patients, which scientists will study more closely.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.